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Abstract
Background Previous studies offer a limited perspective on
the dynamic course of distress in cancer patients and their
partners, owing to a restricted number of assessment points
and the absence of comparison controls drawn from the
general population.
Purpose This study investigated the course of distress
among breast cancer patients and their partners (N=92
couples) in comparison to matched control couples (N=64).
Furthermore, the influence of neuroticism on distress was
investigated.
Method The Hospital Anxiety and Depression Scale was
administered nine times over a 12-month period, and
neuroticism was assessed at the beginning of the study
using the Eysenck Personality Questionnaire.
Results Multilevel analyses revealed that patients were
more distressed during the first 15 months after diagnosis
than nonpatients. A significant portion of the distress that
could not be explained by the cancer experience was
explained by neuroticism.
Conclusion Differences in distress between patients and
comparison-control women are relatively small and de-
creased over time, while distress in male partners was not
elevated in comparison to their controls.
Keywords Anxiety . Depression . Neuroticism .
Multi-level analysis . Intervention
Introduction
Diagnosis and treatment of breast cancer are life-altering
experiences that may evoke considerable emotional distress
in patients and their intimates [1, 2]. Feelings of anxiety
and depression may be understandable reactions to the
changes imposed by the illness and its treatment—threat of
death, loss of mobility, tiredness, or changes in social and
leisure activities. However, when high levels of distress
persist over time, they may become the focus of clinical
concern. Claims are widespread that cancer may induce
enduring high levels of distress in patients and partners [3].
In accordance, the design of clinical trials testing inter-
ventions for the reduction of psychological distress in
couples facing cancer—in either patients or their partners—
has typically been guided by the implicit assumption that,
as a population, unselected couples or individuals facing
cancer are sufficiently distressed to register a benefit for
intervention [4]. However, recruitment of patient samples
lacking in sufficient distress to respond positively has been
offered as a post hoc explanation of null findings in
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intervention trials [5, 6]. The risk is that psychosocial
interventions will be labeled as inefficacious when they
would have been shown to be efficacious when adminis-
tered to a sample with greater distress [4]. Thus, statements
that a substantial portion of the cancer patients suffer from
enduring distress in response to diagnosis and treatment of
breast cancer may be premature or at least in need of greater
precision, particularly given the cross-sectional design and
lack of a control-comparison group [7, 8] in most
descriptive studies. Indeed some studies have even found
that the distress levels in women with breast cancer are
comparable to the levels of distress found in primary-care
samples or individuals of the general population [2, 8–11].
In general, based on such comparisons, sustained elevations
in distress in couples facing cancer appear to be moderate,
at best [12].
Studies that do follow breast cancer patients over time
[13–15] show a decrease in distress within the first months
after the diagnosis (see, for an exception, [2]). Although
these studies offer valuable insights into levels of distress
over time, they typically make use of a restricted number of
assessment points, limiting the understanding that they
provide of the dynamic course of distress. Moreover, there
is a lack of agreement concerning when to expect declines
or increases in distress. For example, some claim an initial
increase following diagnosis that persists during treatment
[16], whereas others indicate that the major threat of
distress lies at the end of treatment [17]. Furthermore, in
the absence of matched comparison controls, it is not clear
whether and when distress levels decrease to the levels
found in the general population. The few longitudinal
studies that include comparison controls offer inconsistent
results [2, 7]. Analyses of the only longitudinal study
investigating distress in couples facing breast cancer and
comparison controls did not take into account the correlat-
ed, nonindependent nature of distress scores within indi-
viduals over time and between individuals within couples
[2]. Ignoring that nonindependence of distress scores—
i.e., accepting each observation of a distress score as
independent—may bias standard errors of statistical tests,
increasing type-I error rates and inflating the statistical
significance of the results.
Distress levels found in cancer patients and their partners
may not only simply be the result of illness-related factors
[18, 19], but may also be explained by personality or
background factors [20]. If a substantial portion of distress
is not explained by cancer experiences but by enduring
personality characteristics, this may have implications for
interventions, as there would be a lower expectation for
alleviating this distress with formal cancer-specific inter-
ventions [21, 22]. A candidate personality trait is the
concept of neuroticism, one of the basic dimensions in the
Big Five model of personality. Neuroticism is indicative of
emotional instability, increasing people’s proneness to
distress in general and in situations of stress specifically
[23]. Its stability has been established across the life span,
indicating that neuroticism is a relatively stable trait that
shows only minor gradual changes over time [24, 25].
Moderate to strong correlations have been found between
neuroticism and distress, raising discussion about possible
contamination. Several studies [25, 26] have shown that,
while distress was susceptible to change as a result of life
events, neuroticism remained stable, favoring its position as
a trait. In addition, it was found that neuroticism is a
predictor of the distress induced by life events, supporting
its importance when examining distress (e.g., [21, 27–29]).
There are some indications that it is also predictive of
distress in persons with cancer [30–31]. Taken together,
these results point at the importance of taking neuroticism
into account when examining the course of distress in
cancer patients.
The aim of the present study is to extend previous
research by investigating the level and course of distress in
women with breast cancer and their partners in comparison
to matched controls from the general population, making
use of nine assessment points between 3 and 15 months
after diagnosis. This number of assessments will provide
more detailed insight into fluctuations in distress over time,
allowing for fewer assessment points in future observation-
al trials and also providing a guide for the choice of
appropriate times for psychosocial interventions. A recent
meta analysis suggests that we should aim for addressing
the short-term burden of distress for some cancer patients,
rather than expecting long-term effects [32]. We seek to
give more precision to this suggestion. Patients and partners
were investigated both as individuals and as part of a
couple, and the nonindependence of scores over time within
individuals and between individuals within couples was
handled appropriately by means of multilevel analysis.
Moreover, distress not explained by cancer was expected to
be partly explained by neuroticism.
Method
Study Design and Participants
Participants were recruited from five hospitals in the
Netherlands. Inclusion criteria were: living with a partner,
willingness by both female patients and male partners to
participate in the study, woman’s age between 30 and
75 years, prognosis of at least 15 months survival, no
previous cancer history for either the women or partner, and
both being fluent in Dutch. In a procedure required by the
hospital Institutional Review Board, women received a
letter from their physician inviting the couple to participate
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in the study. Women interested were encouraged to enlist
their partners and to mail back consent forms. After
approximately 4 weeks, couples who did not return the
consent form were contacted by the study team with a letter
reminding them about the study. In addition, comparison-
control couples were selected from a community sample,
matched on age and geographical region. An exclusion
criterion for both female and male controls was a history of
cancer. Control couples enrolled in the study only if both
partners were willing to participate.
Data Collection
After recruitment, participants were assessed nine times.
The first assessment took place 3 months after diagnosis,
followed by questionnaires every 6 weeks. A total of 284
patient couples were asked to consider participation. In the
end, 92 couples (a response rate of 32%) participated in the
study of which almost all (94%) remained in the study. This
response rate reflects (a) the burden of the intensive design
of the study as patients were asked to complete a broad
range of questionnaires, and (b) perhaps more importantly,
the consent procedure required by the Institutional Review
Board and the initiative it required from the patients to
enroll in the study. Nonetheless, this percentage is
comparable to what has been found in some well-resourced
studies investigating couples [33, 34]. The main reason
(31%) for not participating was that couples indicated that
participating was too great a burden. In addition, 28% of
the couples were simply not interested; in 15% of the cases,
a partner was not willing to participate; 10% indicated that
they wanted to close the cancer history; and another 16% of
the couples gave other reasons for not participating in the
study.
Control couples were selected from a large community
sample (N=2500) of women aged between 30 and 75 years
living with a partner, taken from the registries of the
municipalities in areas covered by the participating hospi-
tals. After inclusion of a new patient couple, a matching
control female of this sample along with her male partner
were approached by a mailed letter containing information
about the study for participation. Control couples had to
respond by mail when they wanted to participate. When a
control couple refused, a similar procedure was applied
until a matching control couple was found. When a
sufficiently large sample of control couples was derived,
the matching procedure was stopped, while the patient
inclusion continued. The matching was continuously
checked at group level to ascertain that the two groups
were adequately matched. In total, N=347 control females
were approached for participation, of whom N=66 were




Participants completed the Hospital Anxiety and Depres-
sion Scale (HADS) [35, 36], a 14-item self-report scale
assessing feelings of anxiety and depressive symptoms over
the last week on a four-point scale (0 to 3). In the present
study, the total score was calculated with a higher score
representing more distress. Cronbach’s alpha for the total
score, averaged over nine assessments, was high, 0.91 for
patients, 0.90 for partners, 0.89 for comparison-control
women, and 0.85 for comparison-control men, supporting
the use of the total scale in this study.
Neuroticism
A short, 12-item version of the widely used Eysenck
Personality Questionnaire [37] was used to assess neuroticism
at T1 (e.g., “Does your mood often go up and down?” or
“Are your feelings easily hurt?”). Response alternatives were
“yes” or “no,” and scores ranged from 0 to 12. Cronbach’s
alpha was 0.83 for patients, 0.84 for partners, 0.84 for
comparison-control women, and 0.83 for comparison-
control men.
Analysis
Patient characteristics and the association between self-
reported treatment characteristics (i.e., being in treatment
and type of treatment: chemo-, radio-, hormonal-, or
alternative therapy), cancer stage, and distress were
explored. Furthermore, multilevel analysis [38], also called
hierarchical linear modeling, was used to investigate the
differences in level and course of distress between patients,
partners, and comparison controls. This is a generalization
of regression analysis designed for nested data sets. In our
data set, repeated measurements were nested in individuals,
and individuals were nested in couples. The correlation
patterns followed from this nesting structure. Thus, the
multilevel analysis accounted simultaneously for the inter-
correlation of distress scores between partners of a dyad
and for the longitudinal character of the data [39]. Analyses
were carried out using MLwiN [40]. Since MLwiN allows
the number of observations per assessment to differ,
missing data were not imputed. A sequence of models
was fitted, and the random effects of these models were
tested using deviance statistics.
First, we investigated the distribution of the variance in
distress across the different levels on the basis of the
interclass correlation coefficient of the unconditional model
(model 1). Next, we tested whether differences in distress
could be explained by being male versus female, by being
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part of a patient couple versus a comparison-control couple,
and by being a patient versus a nonpatient (model 2).
Furthermore, time since diagnosis was entered as a
potential source of variation (model 3). Graphical analysis
of the mean distress scores of all participants at the different
moments in time showed that the distress trajectory was
best represented by a linear equation (i.e., a steady decrease
in distress over time), with a discrepancy from this linear
effect at T1. To test this discrepancy, T1 distress was
included in the model as a dummy variable, representing
distress at 3 months after diagnosis versus later assess-
ments. Differences between individuals and between
couples in the course of distress were represented by
random coefficients for time and the dummy variable for
T1. To achieve a good model fit, we tested whether the
effects of these random effects varied between individuals
and whether they differed between couples, and the
significant random effects were retained. Next, interactions
between groups and the two time variables were tested
(model 4). We also investigated the effect of neuroticism on
distress and whether entering neuroticism into the model
changed earlier results (model 5). Finally, we investigated
the level and rate of distress in the different groups at the




Participants’ characteristics are presented in Table 1.
Patients and partners were properly matched with compar-
ison controls on age, employment status, and education
level. All women with breast cancer received surgery, and
90% (N=83) received additional treatment (i.e., radiother-
apy and/or chemotherapy and/or hormonal therapy). Six-
teen patients (17%) were diagnosed with stage 1, 69 (75%)
with stage 2, and seven (8%) with stage 3 breast cancer.
Among patients, there was no association of stage, active
treatment status, and type of treatment at the first and last
assessment with level of distress, and so these variables were
excluded from further analysis. In Fig. 1, distress trajectories
of patients, partners, and comparison controls are shown.
The distress trajectory of patient and comparison-control
couples in Fig. 1 is the mean distress score at the couple
level.
Level and Course of Distress
The total variance in distress was partitioned over the three
levels; couples, individuals, and time. The amount of variance
was assessed using interclass correlation coefficient of the
unconditional model (i.e., a model without explanatory
variables). The unconditional model (model 1) showed that
a total of 26% of the variance in distress was at the couple
level (10.96/10.96+15.66+15.46), 37% at the individual
level, and 37% at the time level, which indicates that distress
varies between couples, between individuals, and over time.
Next, we entered explanatory variables in four sequential
steps. First, we entered group into the equation (i.e., male,
patient-couple, patient). This model (model 2) fitted the
data better than the model without explanatory variables
(χ2=23, df=4, p<0.001) and showed that the average
distress score of comparison-control women was 6.62 (SE=
0.65) and that patients were more distressed than compar-
ison-control women, β=1.78 (SE=0.91), p<0.05. Men
were not significantly less distressed than women, β=
−0.71 (SE=0.70), p>0.05, and patient couples (aggregated
scores for patients and partners) were not significantly more
distressed than comparison-control couples, β=0.64 (SE=
0.85), p>0.05.
Table 1 Descriptive characteristics
Patients Comparison-control women Partners Comparison-control men
Mean age (SD) 53 (9.3) 53 (10.0) 54 (9.4) 56 (9.9)
Employment (yes) 44 (49%) 32 (50%) 62 (67%) 43 (67%)
Education level
Lower level 28 (30%) 18 (28%) 28 (30%) 10 (16%)
Secondary level 40 (44%) 24 (38%) 33 (36%) 22 (34%)
Higher level 24 (26%) 22 (34%) 31 (34%) 32 (50%)
Patients at T1 at T9
In treatment (yes) 59 (64%)a 28 (33%)a
Chemotherapy 27 (46%)b 0
Radiotherapy 22 (37%)b 0
Hormonal therapy 13 (22%)b 24 (86%)b
Alternative therapy 4 (7%)b 7 (25%)b
a Percentage of the total number of patients included in the study at T1 (N=92) and T2 (N=84)
b Percentage of the number of people in treatment
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Second, we entered time, both as a linear equation
coefficient and as a dummy variable for T1 (model 3).
Since the effect of time on distress may differ between
individuals and couples, we allowed the time variables to
vary randomly at both the couple and individual level.
Deviance tests revealed that time as a linear equation had a
random effect at the couple level (χ2=13, df=1, p<0.001)
but not at the individual level (χ2=3, df=1, p>0.05),
indicating that individuals within couples showed rather
similar distress trajectories, while couples were more
distinct. Time at T1 had a random effect at both the
individual (χ2=25, df=1, p<0.001) and the couple level
(χ2=30, df=1, p<0.001), indicating that large differences
in initial distress scores existed between couples and
between individuals. This model fitted the data significantly
better than the model without explanatory time variables
(χ2=255, df=5, p<0.001). The fixed part of the model
showed that participants reported significantly more distress
at T1, β=0.72 (SE=0.35), p<0.05, and that distress
decreased over time, β=−0.29 (SE=0.05), p<0.001.
Third, interactions between group and the two time
variables were entered into the equation and the significant
fixed effects were retained (model 4). Patient couples
showed a stronger decrease in distress over time, β=−0.23
(SE=0.09), p<0.05, than comparison-control couples.
Patients scored relatively low on distress at T1, β=−2.33
(SE=0.62), p<0.001, in comparison to their subsequent
scores. This finding shows that the discrepancy in the
steady decrease in distress over time observed at T1, as
shown in the preliminary graphical analyses, was due to the
fact that patients reported greater distress at several points
other than T1. The model with the two significant
interaction effects fitted the data better than the previous
model (χ2=16, df=2, p<0.001).
Fourth, we entered neuroticism into the equation at the
individual level (model 5). Results showed that a large part
of the variation in distress between individuals, which was
not explained by group and time, was explained by
neuroticism (χ2=301, df=2, p<0.001). Individuals who
scored higher on neuroticism were more distressed, β=0.90
(SE=0.08), p<0.01. This association was not qualified by
group but was qualified by time. That is, the association
between neuroticism and distress decreased over time, β=
−0.03 (SE=0.01), p<0.001. See Table 2.1
Finally, we investigated the results at the end of the
study (i.e., T9). Results showed that, 15 months after the
diagnosis, patients were more distressed than comparison-





















3 mos 4.5 mos 6 mos 7.5 mos 9 mos 10.5 mos 12 mos 13.5 mos 15 mos
Patient couples
Comparison-control couples
Fig. 1 Course of distress
1 To test whether the skewness of the continuous distress measure
impacted the results, the residual variance was allowed to differ
between patients and nonpatients. These additional analyses showed
no differences in the effects tested.
2 A separate investigation of the anxiety and depression subscales of
the HADS produced a similar pattern of the results as the full scale
with only two exceptions. That is, males scored significantly lower on
anxiety than women β=−0.98 (SE=0.42), p<0.05, but no differences
between men and women were found in depressive symptoms, β=
0.26 (SE=0.35), p>0.05. Moreover, overall, patients were not found
to report more anxiety, β=0.72 (SE=0.55), p>0.05, but they were
found to report more depressive symptoms than control women β=
1.06 (SE=0.45), p<0.05.
ann. behav. med. (2008) 36:141–148 145
Discussion
Results showed that women with breast cancer had
enduring but only modestly higher levels of distress than
comparison-control women. Although the level of distress
decreased over time, 15 months after diagnosis, patients
were still more distressed than comparison-controls and
also more than their partners. Peak levels of distress
followed by a decline thereafter were observed at T2
(during adjuvant treatment) and T6 (after end of treatment).
While some researchers claim an initial increase in distress
after diagnosis that persists during treatment [16], our
findings indicate a decline after treatment. It also corrob-
orates the claim of an increase after end of treatment [17],
although this change seems to be only transient.
A possible explanation for the relatively high levels of
distress at T2 and T6 might be found in treatment
characteristics. In the Netherlands, across hospitals, the
same standardized treatment protocol for breast cancer
patients is applied [41]. Almost all women undergo surgery
within 2–4 weeks after diagnosis followed by adjuvant
treatment in more than 80% of the cases. Adjuvant therapy
includes radiation therapy and/or chemotherapy. Radiation
therapy will take approximately 7 weeks while chemother-
apy may take more than 12 weeks. Taking into account an
average 4-week waiting period after the procedure, treat-
ment intensity will be at its peak around T2 (approximately
18 weeks after diagnosis). This may explain the relatively
high distress in patients at this assessment point. Six
months later, patients will have ended treatment which
may explain the relatively high levels of distress in patients
at T6. Ending treatment might be associated with an
increase in distress as people may lose the security
associated with being in treatment and in regular contact
with healthcare professionals it provides [42]. Future
studies may investigate this possibility further by paying
more attention to the emotional impact of specific illness
events (see for an example, [14]).
The findings in the present study may have implications
for intervention studies. First, it could be concluded that,
although women with breast cancer reported more distress
than comparison controls, over time, women with breast
cancer and comparison controls become more similar.
Consequently, trials should be implemented relatively soon
after diagnosis (e.g., within the first 6 months after
diagnosis) with a limited time to follow-up, as otherwise
Table 2 Predictors of distress
Distress as Continuous variable
Model 1 Model 2 Model 3 Model 4 Model 5
β SE β SE β SE β SE β SE
Fixed effect
Intercept 7.17*** 0.36 6.62*** 0.65 7.91*** 0.70 7.08*** 0.74 6.71*** 0.65
Male −0.71 0.70 −0.79 0.69 −0.80 0.69 0.16 0.56
Patient couple 0.64 0.85 0.38 0.80 1.53 0.89 1.35 0.76
Patient 1.78* 0.91 1.45 0.90 2.02* 0.92 1.94** 0.75
Time −0.29*** 0.05 −0.15* 0.07 −0.16* 0.07
Time_1a 0.72* 0.35 1.40*** 0.39 1.40*** 0.40
Patient × Time_1 −2.33*** 0.62 −2.36*** 0.63
Patient couple × Time −0.23* 0.09 −0.22* 0.09
Neuroticism 0.90*** 0.08
Neuroticism × Time −0.03** 0.01
Random effect
Couple level
Interceptb 10.96*** 2.45 11.34*** 2.35 21.45*** 3.86 20.97*** 3.81 18.82*** 3.21
Time 0.25*** 0.05 0.24*** 0.05 0.24*** 0.05
Time_1 3.40 2.49 3.88 2.41 4.68 2.49
Individual level
Interceptb 15.66*** 2.00 13.75*** 1.78 14.91*** 1.90 14.84*** 1.89 9.33*** 1.27
Time_1 9.54** 2.7 7.87** 2.56 7.60** 2.54
Time level
Interceptb 15.46*** 0.45 15.46*** 0.45 12.37*** 0.40 12.37*** 0.40 12.36*** 0.41
Significance was tested two-tailed
*p<0.05; **p<0.01; ***p<0.001
a Time_1=dummy variable of distress at T1
b The variance in distress at the Couple, Individual and Time levels
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effects of the intervention will dissipate with time and
would require patients to become less distressed than
members of the general community in order for an effect
to be registered. This finding is in accordance with a recent
meta-analysis suggesting that we should aim for addressing
the short-term burden of distress for some cancer patients
rather than expecting long-term effects [32].
The finding that differences in distress between patients
and comparison-control women are small and decrease over
time also indicates that interventions aimed at alleviating
distress would require a very large number of unselected
patients to detect a treatment effect relative to the decrease
in distress that is likely to occur without a formal
intervention. Therefore, instead of treating all patients, it
may be much more effective to pre-select patients with
elevated distress scores, consistent with recent recommen-
dations [43, 44]. The few studies to date that do find a
treatment by group effect [45, 46] tended to pre-select
patients with elevated distress scores. In both of these
studies, patients were selected for heightened distress, and
both the treatment and control condition had at least 50
patients each. However, the bulk of the psychological
interventions for cancer patients do not pre-select clinically
distressed patients and have fewer than 50 patients in the
small condition [47]. Therefore, most psychological inter-
ventions studied in oncology may be underpowered and
otherwise target an unselected sample of patients unlikely
to register an effect. A consequence may be that many
interventions are dismissed as lacking in efficacy that might
have proven efficacious in a sufficiently powered trial with
patients pre-selected for distress [48].
Furthermore, the present results suggest that partners of
women with breast cancer are not a suitable target for
intervention studies directed at alleviating their distress, as
they were not found to be more distressed than male
comparison controls. It might be more useful to engage
partners in efforts to address relationship issues or as
collaborators in efforts to reduce the distress in women with
breast cancer [29]. Finally, the finding that neuroticism was
a strong predictor of psychological distress may have
implications for interventions, since distress experienced
by individuals scoring high on neuroticism may be less
responsive to interventions [26, 27].
Our study has some distinct strengths, such as a
longitudinal design with multiple assessments, the inclusion
of patients and partners as well as comparison controls, and
the use of a more sophisticated method of analysis, but it
also has some notable limitations. The response rate in the
patient group was relatively low. This may have affected
the findings, in particular, the level of distress among
patient couples. The more distressed couples may have
been more likely to refuse participation, causing an
underestimation of the actual level of distress in the larger
pool of patient couples. We strongly suspect that the
response rate was affected by the conditions of recruitment
imposed by the Institutional Review Board (e.g., not being
allowed to offer an even minimal financial incentive to
patients or to approach patients directly, thus leaving the
initiative to them). Given that other studies might increas-
ingly face similar constraints, it is important to investigate
whether such recruitment strategies actually yield different
levels in observed distress than what might be found in a
population that investigators were able to access directly.
Nonetheless, it should be noted though that the level and
course of distress found in the present study of partnered
patients are in line with other studies using the HADS in
women with breast cancer [9, 10, 49, 50].
Different mechanisms likely underlie the recruitment rate
in the control group. They might have lacked the motivation
that their participation would contribute to an understanding
of how the predicament of women suffering from breast
cancer and their partners adjust to the disease. This was
underscored by a more impersonal recruitment strategy,
unconnected with a setting in which they were receiving any
treatment. In general, characteristics of comparison control
patients leading to their recruitment and retention in studies
may differ from those of medically ill patients, a reasonable
assumption that deserves further investigation.
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